铁补充剂对患有红色素质原体的个体的影响
Ida M Heerfordt1, Catharina M Lerche2, Peter A Philipsen3
1Department of Dermatology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Denmark; Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Denmark.
Photodiagnosis and photodynamic therapy
|May 11, 2024
概括
口服铁补充剂在患有铁缺乏症的血红发育原症 (EPP) 患者中补充了铁储量. 然而,铁疗法可以提高原氨酸IX (PPIX) 水平和肝酶,需要仔细监测.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
背景情况:
- 红色人造原型 (Erythropoietic protoporphyrias,简称EPP) 是一种遗传性疾病,其特征是由原型第九种 (PPIX) 的积累.
- 积聚PPIX会导致光敏感性,并增加患肝病的风险.
- 许多EPP患者也出现缺铁和贫血,使疾病管理复杂化.
研究的目的:
- 调查诊断为EPP和铁缺乏症的患者口服铁补充剂的结果.
- 评估铁治疗对EPF患者PPIX水平,血红蛋白和铁参数的影响.
- 在这个患者群体中确定与铁补充剂相关的潜在不良事件.
主要方法:
- 进行了一项系统的文献审查,以确定EPP患者口服铁补充剂的现有研究.
- 铁补充剂 (每天2个月服用330毫克铁酸盐) 给了10名已记录铁缺乏症的EPP患者.
- 测量结果包括PPIX水平,血红蛋白,费里丁和血亚氨酸酶的变化,以及不良事件监测.
主要成果:
- 补充铁导致EPP患者的费里水平增加.
- 十分之七的患者经历了红细胞PPIX水平在铁治疗两个月后的增加.
- 四名患者的贫血状况有所改善,血红蛋白水平正常化,而血亚氨酸氨酸酶的暂时升高也被观察到.
结论:
- 铁缺乏症EPP患者的口服铁补充剂可以补充铁储量并改善贫血.
- 铁疗法可能导致PPIX的升高和肝酶 (血中氨酸酶) 的暂时增加,需要谨慎监测.
- 对于接受铁疗法的EPF患者,建议对光敏度,PPIX水平,血红蛋白和肝酶进行密切监测.
相关概念视频
01:27Disorders of Erythrocytes
929
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
929
01:24Factors Affecting Erythropoiesis
3.2K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.2K
01:14Erythropoiesis
4.2K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.2K
01:22Lifecycle of Erythrocytes
2.0K
Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups....
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups....
2.0K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
00:57The Periodic Table and Organismal Elements
178.2K
Overview
178.2K